Downregulation of doxorubicin-induced myocardial apoptosis accompanies postnatal heart maturation.
Doxorubicin is a highly effective chemotherapeutic agent used for treating a wide spectrum of tumors, but its usage is limited because of its dose-dependent cardiotoxicity, especially in pediatric patients. Accumulating evidence indicates that caspase-dependent apoptosis contributes to the cardiotoxicity of doxorubicin. However, less attention has been paid to the effects of age on doxorubicin-induced apoptosis signaling in myocardium. This study focused on investigating differential apoptotic sensitivity between neonatal and adult myocardium, in particular, between neonatal and adult cardiomyocytes in vivo. Our results show that caspase-3 activity in normal mouse hearts decreased by ≥ 20-fold within the first 3 wk after birth, associated with a rapid downregulation in the expression of key proapoptotic proteins in intrinsic and extrinsic pathways. This rapid downregulation of caspase-3 activity was confirmed by immunostaining for cleaved caspase-3 and terminal deoxynucleotidyl transferase dUTP-mediated nick-end label staining. Doxorubicin treatment induced a dose-dependent increase in caspase-3 activity and apoptosis in neonatal mouse hearts, and both caspase-8 and caspase-9 activations were involved. Using transgenic mice with a nuclear localized LacZ reporter gene to label cardiomyocytes in vivo, we observed a fourfold higher level of doxorubicin-induced cardiomyocyte apoptosis in 1-wk-old mice compared with that in 3-wk-old mice. This study points to a major difference in apoptotic signaling in doxorubicin cardiotoxicity between neonatal and adult mouse hearts and reveals a critical transition from high to low susceptibility to doxorubicin-induced apoptosis during postnatal heart maturation.
Riley Heart Research Center, Wells Center for Pediatric Research, Department of Pediatrics, Indiana University, School of Medicine, Indianapolis, Indiana 46202-5225, USA.
Jianjian
J
Shi
Lumin
L
Zhang
Yi-Wei
YW
Zhang
Michelle
M
Surma
R
R
Mark Payne
Lei
L
Wei
D000818:Animals; D000831:Animals, Newborn / Q000502:physiology; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D051017:Apoptosis Regulatory Proteins / Q000096:biosynthesis / Q000235:genetics; D020169:Caspases / Q000502:physiology; D015536:Down-Regulation; D004317:Doxorubicin / Q000494:pharmacology*; D004789:Enzyme Activation / Q000502:physiology; D006321:Heart / Q000254:growth & development*; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D007763:Lac Operon / Q000235:genetics; D051379:Mice; D008822:Mice, Transgenic; D008929:Mitochondria, Heart / Q000502:physiology; D009206:Myocardium / Q000166:cytology*; D032383:Myocytes, Cardiac / Q000502:physiology; D015398:Signal Transduction / Q000502:physiology; D013347:Subcellular Fractions / Q000502:physiology
D000903:Antibiotics, Antineoplastic; D051017:Apoptosis Regulatory Proteins; D004317:Doxorubicin; D020169:Caspases